Decoding what FDA BIMO/PAI inspectors actually look for and why
Designing inspection-ready systems that withstand real-world pressure
Data integrity and story coherence: The real drivers of first-cycle approvals
Communication choreography: Before, during, and after the inspection
Tailored guidance: Differentiating strategies for small biotechs vs. mid-size companies
Addressing recent site performance concerns and rebuilding trust when site credibility is questioned
Identifying common gaps in oversight, governance to avoid actively monitoring site work
Understanding policies and competing with limited resources at sites
Enhancing site staff training, culture and accountability of clinical research
Understand the foundational requirements for AI
Differentiate between realistic and unrealistic expectations of AI and agents
Identify strategies for prioritizing AI use cases
Overcoming the hype: Moving from pilot projects to real-world applications of AI in pharma
In a conservative and cautious industry, are we ready for AI?
Reskilling for the AI Age: Preparing today’s workforce for the future, equipped with data-centric skills
Unveiling but disparaging AI myths in clinical research
Overcoming financial constraints when budgets are limited and resources tight
Fierce site competition: How start-ups can compete with established companies for sites
Utilizing effective planning to improve study and program efficiency without compromising patient safety
Agile and adaptable: Being prepared to adjust your strategy and approach as needed
Trends observed during the JP Morgan Healthcare conference
Navigating geopolitical complexity, regulatory shifts, and a more selective funding environment
Sponsor Accountability: Ultimate responsibility for regulatory submissions remains with the sponsor.
Target Product Profile Integration: Acts as a strategic anchor for submission quality and alignment.
Effective Oversight: Governance, communication, and risk management ensure compliance in outsourced settings.
Emphasize the critical role of LTFU in cell and gene therapy trials and why early planning matters
Outline key logistics and operations considerations (site readiness, patient tracking, communication pathways) that minimize follow-up costs and support successful LTFU models
Highlight the importance of early patient education and engagement and use of remote or virtual visits to improve retention and compliance
Share broad learnings from past programs where proactive LTFU planning facilitated compliance and improved cost predictability
Posts navigation
